Castration Levels of Testosterone

1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
EnzalutamidePhase 11 trial
Active Trials
NCT03751436Completed10Est. Aug 2023
Knight Therapeutics
Knight TherapeuticsQC - Montréal
1 program
Cytology Specimen Collection ProcedureN/A1 trial
Active Trials
NCT02228265Completed41Est. Feb 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AbbVieEnzalutamide
Knight TherapeuticsCytology Specimen Collection Procedure

Clinical Trials (2)

Total enrollment: 51 patients across 2 trials

NCT03751436AbbVieEnzalutamide

Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer

Start: Aug 2019Est. completion: Aug 202310 patients
Phase 1Completed
NCT02228265Knight TherapeuticsCytology Specimen Collection Procedure

Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide

Start: Mar 2013Est. completion: Feb 202041 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space